Urovant Sciences

Improving quality of life through innovations in urology.

Vibegron (RVT-901)

Our lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. We anticipate initiating an international Phase 3 registration program for vibegron in 2017.

LEARN MORE

women-sleeping

Overactive Bladder (OAB)

Overactive bladder (OAB) is a condition that affects potentially 46 million American adults. The most common symptoms of OAB include the experience of sudden urges to urinate that cannot be controlled, frequent urination, and urinary incontinence due to involuntary contractions of the detrusor muscle. While several conditions may contribute to signs and symptoms of overactive bladder, the underlying cause of OAB remains unclear.

LEARN MORE

woman-drinking-on-hike

Latest News

The latest posts and articles

Urovant Sciences Appoints Keith A. Katkin as CEO

Former CEO of Avanir Pharmaceuticals joins Roivant family of companies Plans to initiate confirmatory Phase 3 program of vibegron by…

Roivant Sciences Launches Urovant to Develop Innovative Therapies in Urology

Urovant has licensed vibegron, a Phase 3-ready selective β3-adrenergic agonist for the treatment of overactive bladder, from Merck Urovant plans…

Copyright 2017 © All Rights Reserved